About this medicine

Intuniv is designed to release guanfacine gradually. Psychological, educational and social support remain part of ADHD care.

What is this medicine used for?

The licence covers ages 6–17 when stimulants are unsuitable, not tolerated or ineffective. NICE identifies adult guanfacine as off-label and requiring tertiary ADHD advice.

For children, this product’s licensed age range is separate from its place in the NICE treatment sequence. The ADHD article explains when this option may be considered after assessment, environmental changes and review of earlier treatment. Follow the exact formulation’s prescribing information and the agreed specialist monitoring plan.

Which warning signs need help?

Seek urgent help for collapse, marked faintness, a very slow pulse or new suicidal thoughts. Severe headache or confusion after abrupt withdrawal needs urgent assessment. The checked product carries UK additional-monitoring status; this is not an FDA boxed-warning designation.

How do I take it safely?

The SmPC starts at 1 mg once daily, increasing by no more than 1 mg weekly. Maintenance and maximum doses depend on age, weight and response. Do not crush, chew or split Intuniv, or take it with grapefruit juice or a high-fat meal.

The usual maintenance range is 0.05–0.12 mg/kg/day. The labelled maximum is 4 mg/day for children aged 6–12 weighing at least 25 kg; adolescent maxima vary by weight, up to 7 mg/day. These are specialist prescribing boundaries, not a home titration guide.

What side effects should I know about?

Sleepiness, fatigue, headache and abdominal pain are common. Weight gain and dizziness may also require review.

Who needs extra care with this medicine?

Tell the specialist about fainting, heart problems, low blood pressure and other psychiatric conditions. Allergy to guanfacine or a product ingredient prevents use.

Dehydration can worsen fainting risk. Heart block, QT prolongation or a family history of sudden unexplained death need particular assessment. Kidney or liver impairment can require dose reduction.

Can it affect my other medicines?

CYP3A4 inhibitors or inducers can change exposure. Sedatives, alcohol and medicines lowering blood pressure or pulse can add to adverse effects.

Examples include ketoconazole, which can raise exposure, and carbamazepine, which can reduce it. Starting or stopping such medicines may require retitration; the prescriber should manage this rather than the patient compensating with extra tablets.

What check-ups will I need?

Baseline cardiovascular and growth checks are followed by weekly review during titration, at least three-monthly in the first year and six-monthly thereafter, with additional checks after dose changes.

Longer-term review also considers whether benefit still justifies treatment. Any trial off medication must be planned with the specialist because abrupt withdrawal can raise blood pressure.

What about pregnancy, breastfeeding and age?

The product information advises against using guanfacine during pregnancy. Breastfeeding decisions need medical advice. Safety and efficacy are not established for children under 6 or adults in this licence.

What if I miss a dose or want to stop?

If two or more consecutive doses are missed, ask the prescriber about restarting. When stopping, the SmPC limits reductions to 1 mg every 3–7 days, with pulse and blood-pressure monitoring.

How does it work?

Guanfacine acts at a particular type of receptor, a protein that receives chemical messages in the brain. It activates alpha-2A receptors, which respond to noradrenaline, a chemical messenger. The full connection between this action and improvement in attention-deficit/hyperactivity disorder (ADHD) symptoms is not yet understood.

How Brain Cells Communicate

Norepinephrine carries messages between nerve cells and also helps regulate activity in the body. Its receptors come in several types, with alpha-2A naming one of those receiving sites. Activating a receptor starts a response within the cell, but that response depends on the site involved and its place in a network. A receptor used in one brain pathway therefore need not have exactly the same effects everywhere.

What is known: Alpha-2A receptors are one way that cells receive norepinephrine messages.

What remains uncertain: Their presence does not show that a person’s attention difficulties have a single chemical cause.

Norepinephrine: Alpha-2A receptor

A messenger acts at a solid membrane receptor; protein coupling inside the cell illustrates a signaling response, rather than passage through an ion pore. Norepinephrine: A messenger can change signaling through its receptor. Alpha-2A receptor: This receptor symbol identifies a function, not a molecular structure. Cell response: The arrow represents a signaling response, not movement through a pore.
  1. Norepinephrine

    A messenger can change signaling through its receptor.

  2. Alpha-2A receptor

    This receptor symbol identifies a function, not a molecular structure.

  3. Cell response

    The arrow represents a signaling response, not movement through a pore.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

Norepinephrine can activate alpha-2a receptor and change signaling in the cell.

Alpha-2A receptors are one way that cells receive norepinephrine messages. Simplified illustration of the process; individual responses vary.
About this illustration

Norepinephrine; Alpha-2A receptor; Cell signaling. Their presence does not show that a person’s attention difficulties have a single chemical cause.

This is a simplified illustration. It does not show exactly how a medicine fits into a protein or predict a dose or response to treatment.

How the Medication Changes Signaling

Guanfacine is an agonist, meaning it activates a receptor rather than blocking its activation. It binds more strongly to alpha-2A receptors than at the related alpha-2B and alpha-2C types in laboratory binding studies. The term binding affinity describes how strongly a substance attaches to a target under those conditions. That preference identifies a principal target; it is not a percentage showing how much attention or impulse control will improve.

What is known: Guanfacine activates alpha-2A receiving sites in the brain.

What remains uncertain: The complete sequence from this receptor action to ADHD benefit remains uncertain.

Guanfacine: Alpha-2A receptor

A terracotta medicine symbol activates a membrane receptor; intracellular protein coupling represents a response without an ion pore. Guanfacine: The oval identifies the medicine acting at the Alpha-2A receptor. It is a concept symbol, not a molecular shape or binding pose. Alpha-2A receptor: This receptor symbol identifies a function, not a molecular structure. Guanfacine: activation: The arrow represents a signaling response, not movement through a pore.
  1. Guanfacine

    The oval identifies the medicine acting at the Alpha-2A receptor. It is a concept symbol, not a molecular shape or binding pose.

  2. Alpha-2A receptor

    This receptor symbol identifies a function, not a molecular structure.

  3. Guanfacine: activation

    The arrow represents a signaling response, not movement through a pore.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

Guanfacine activates alpha-2A receptors. This receptor action does not fully explain improvement in ADHD.

Guanfacine activates alpha-2A receiving sites in the brain. Simplified illustration of the process; individual responses vary.
About this illustration

Guanfacine; Alpha-2A activation; Changed signaling. The complete sequence from this receptor action to ADHD benefit remains uncertain.

This is a simplified illustration. It does not show exactly how a medicine fits into a protein or predict a dose or response to treatment.

A Closer Look at the Molecular Level

By acting at these central receptors, meaning receptors in the brain, guanfacine can reduce sympathetic nerve signals sent to the heart and blood vessels. Sympathetic signals are part of the body’s automatic control system and help adjust activity in response to demands. Reducing them can slow the heart and reduce resistance to blood flow as vessels relax, lowering blood pressure. These body effects help explain why pulse and blood pressure are followed during treatment, alongside attention and everyday functioning.

What is known: Guanfacine’s receptor action can affect both heart rate and how tightly blood vessels contract.

What remains uncertain: A change in pulse or pressure does not measure how much ADHD symptoms have improved.

How the process works

  1. Central receptor
  2. Reduced nerve output
  3. Pulse and pressure
Guanfacine’s receptor action can affect both heart rate and how tightly blood vessels contract. Simplified illustration of the process; individual responses vary.
About this illustration

Central receptor; Reduced nerve output; Pulse and pressure. A change in pulse or pressure does not measure how much ADHD symptoms have improved.

This is a simplified illustration. It does not show exactly how a medicine fits into a protein or predict a dose or response to treatment.

How does it affect my body?

Reduced sympathetic nerve activity can lower heart rate and blood pressure. These physiological effects help explain fainting and dizziness risks.

How does my body process it?

CYP3A4 and CYP3A5 process guanfacine. Both liver and kidney function can affect exposure; its elimination half-life is approximately 18 hours.

How do treatment options differ?

It offers a different non-stimulant mechanism from atomoxetine. Individual suitability depends on benefit, sedation, cardiovascular effects and the treatment pathway, not a universal ranking.

Immediate-release guanfacine is not interchangeable with Intuniv milligram for milligram. Prolonged release changes the concentration profile; an equivalent ingredient name does not establish an equivalent product.

A closer look at the science

It preferentially activates alpha-2A adrenergic receptors. Preclinical evidence links these receptors to signalling in the prefrontal cortex and basal ganglia; this is not proof of a single complete ADHD mechanism.

Guanfacine hydrochloride is a hydrochloride salt. The drawing shows the neutral parent, guanfacine, and excludes the hydrochloride component.

Chemical formula: C9H9Cl2N3O · HCl

C, H, N, O and Cl denote chemical elements where present; the numbers count atoms. The neutral parent composition is C9H9Cl2N3O; the added HCl describes the hydrochloride salt. Composition does not specify the tablet or capsule release rate.

Verified PubChem 2D depiction of neutral guanfacine; hydrochloride component omitted.
NCBI PubChem CID 3519. Lines represent bonds, unlabeled corners are carbon, and many hydrogen atoms are omitted. This is connectivity, not a receptor binding pose.

The neutral parent drawing and hydrochloride salt formula identify different, explicitly distinguished chemical species.

How was this medicine developed?

The Scottish Medicines Consortium accepted Intuniv for the specified paediatric ADHD indication in 2016. That decision concerns NHS Scotland and does not create identical access arrangements across the UK.

Sources and References

  1. Intuniv 1 mg prolonged-release tablets: SmPC, sections 4–5

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  2. Intuniv 1, 2, 3 and 4 mg prolonged-release tablets: patient leaflet, sections 1–4

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  3. Guanfacine (Intuniv), SMC 1123/16: advice and evidence, pages 1–7

    Scope: United Kingdom product information.

  4. ADHD: diagnosis and management, NG87 recommendation 1.7.17

    Scope: NICE guidance for England; application in other UK nations determined separately.

  5. Intuniv: current prescribing information
  6. ADHD: full recommendations PDF

    Scope: United Kingdom; NICE recommendations require attention to national implementation and local pathways.

  7. Intuniv: FDA label linked by Drugs@FDA
  8. Guanfacine: verified parent compound, PubChem CID 3519

Shared scientific background. Some references are US product pharmacology or international chemical records; UK product details and prescribing information are verified separately.

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top